Featured Content
We're under way...
The ASCO '13 annual meeting abstracts were just released on Wednesday, and we're seeing a lot of media coverage. OBR covered the ASCO presscast the same day and is featured in a blog titled "ASCO '13: Studies Highlight Resource utilization, Immunotherapy, Targeted Therapy, and Physical Fitness".
Thomas, Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors
Doctors Should Discuss Financial Concerns of Cancer Patients
(DukeHealth.org) May 16, 2013 - Most cancer patients would like to talk about the cost of their care with their doctors, but often don't because they fear the discussion could compromise the quality of their treatment, researchers at Duke Cancer Institute report.
Commentary: Times certainly have changed. In the past our role as care givers was really only to discuss the effectiveness...
 |
Our free daily oncology focused e-news service.
Subscribe» | Search Archives» |
Today's News
Novartis Drug Afinitor Significantly Extended Time Without Disease Progression in Women with HER2 Positive Advanced Breast Cancer
(Novartis) May 17, 2013 - Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced breast cancer showed that Afinitor (everolimus) tablets in combination with trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival (PFS) after prior therapy when compared to treatment with placebo plus trastuzumab and vinorelbine,meeting the study's primary endpoint.
read corporate press release »
MGH, AstraZeneca Partner to Create New Drug Combos
(Boston Globe) May 20, 2013 - Advances in genetic profiling have allowed doctors to match more of their cancer patients with treatments that will target their particular illnesses. But for some about one-third of cancer patients, there are no good matches, leaving them with only conventional chemotherapies and radiation.
read article (paid subscription required) »
News Story Commentary By Academic and Community Oncologists
|
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape. OBR Job BoardNovocure has posted 3 new jobs and Sarah Cannon has 1 job posted on the OBR Job Board. |
The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™
View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results
Date: June 3, 2013
Company: GlaxoSmithKline
Product: dabrafenib
Date: June 5, 2013
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)
Date: July 15, 2013
Company: Boehringer Ingelheim Pharmaceuticals
Product: afatinib (BIBW 2992)
OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.